Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was incorporated in 2017 and is headquartered in Redwood City, California.

Biomea Fusion, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

SAN CARLOS, CALIF., DEC. 17, 2025 (GLOBE NEWSWIRE) -- BIOMEA FUSION, INC. (BIOMEA) (NASDAQ: BMEA), A CLINICAL-STAGE DIABETES AND OBESITY COMPANY, TODAY ANNOUNCED THAT MICK HITCHCOCK, PH.D.

BIOMEA FUSION TO PRESENT AT THE 44TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

SAN CARLOS, CALIF., DEC. 09, 2025 (GLOBE NEWSWIRE) -- BIOMEA FUSION, INC. (NASDAQ: BMEA), A CLINICAL STAGE DIABETES AND OBESITY COMPANY, TODAY ANNOUNCED THE RELEASE OF A KOL INTERVIEW DURING THE 23RD WORLD CONGRESS ON INSULIN RESISTANCE, DIABETES & CARDIOVASCULAR DISEASE (WCIRDC 2025) FEATURING DR. RALPH DEFRONZO, PROFESSOR OF MEDICINE AND CHIEF OF THE DIABETES DIVISION AT UT HEALTH SAN ANTONIO. THE INTERVIEW HIGHLIGHTS THE GROWING BODY OF PRECLINICAL AND CLINICAL FINDINGS SUPPORTING THE USE OF ICOVAMENIB IN PATIENTS WITH DIABETES.

BIOMEA FUSION ANNOUNCES KOL PRESENTATION AND INTERVIEW ON MENIN AND ICOVAMENIB AT WCIRDC 2025

DURABLE GLYCEMIC AND C-PEPTIDE IMPROVEMENTS WITH ICOVAMENIB IN INSULIN-DEFICIENT TYPE 2 DIABETES DURABLE GLYCEMIC AND C-PEPTIDE IMPROVEMENTS WITH ICOVAMENIB IN INSULIN-DEFICIENT TYPE 2 DIABETES

BIOMEA FUSION PRESENTS COVALENT-111 STUDY RESULTS AT THE 23RD WORLD CONGRESS ON INSULIN RESISTANCE, DIABETES & CARDIOVASCULAR DISEASE (WCIRDC)

SAN CARLOS, CALIF., DEC. 01, 2025 (GLOBE NEWSWIRE) -- BIOMEA FUSION, INC. (BIOMEA OR BIOMEA FUSION OR THE COMPANY) (NASDAQ: BMEA), A CLINICAL-STAGE DIABETES AND OBESITY COMPANY, TODAY ANNOUNCED THAT IT HAS BEEN SELECTED FOR AN ORAL PRESENTATION OF ITS LONG-TERM ICOVAMENIB FOLLOW UP DATA AT THE 23RD WORLD CONGRESS ON INSULIN RESISTANCE, DIABETES & CARDIOVASCULAR DISEASE (WCIRDC) TAKING PLACE IN LOS ANGELES, CALIFORNIA ON DECEMBER 3-6, 2025.

BIOMEA FUSION ANNOUNCES ORAL PRESENTATION OF ICOVAMENIB AT THE 23RD WORLD CONGRESS ON INSULIN RESISTANCE, DIABETES & CARDIOVASCULAR DISEASE (WCIRDC)

SAN CARLOS, CALIF., DEC. 01, 2025 (GLOBE NEWSWIRE) -- BIOMEA FUSION, INC. (BIOMEA OR THE COMPANY) (NASDAQ: BMEA), A CLINICAL-STAGE DIABETES AND OBESITY MEDICINES COMPANY, TODAY ANNOUNCED THAT ON NOVEMBER 26, 2025, THE COMPENSATION COMMITTEE OF BIOMEA'S BOARD OF DIRECTORS GRANTED ONE NEW EMPLOYEE NON-QUALIFIED STOCK OPTIONS TO PURCHASE 7,500 SHARES OF THE COMPANY'S COMMON STOCK.

BIOMEA FUSION, INC. REPORTS INDUCEMENT GRANT UNDER NASDAQ LISTING RULE 5635(C)(4)

SAN CARLOS, CALIF., NOV. 24, 2025 (GLOBE NEWSWIRE) -- BIOMEA FUSION, INC. (BIOMEA OR BIOMEA FUSION OR THE COMPANY) (NASDAQ: BMEA), A CLINICAL-STAGE DIABETES AND OBESITY COMPANY, TODAY ANNOUNCED THAT IT WILL PARTICIPATE IN THE UPCOMING INVESTOR CONFERENCES:

BIOMEA FUSION TO PARTICIPATE AT UPCOMING INVESTOR CONFERENCES

SAN CARLOS, CALIF., NOV. 10, 2025 (GLOBE NEWSWIRE) -- BIOMEA FUSION, INC. (BIOMEA OR BIOMEA FUSION OR THE COMPANY) (NASDAQ: BMEA), A CLINICAL-STAGE DIABETES AND OBESITY COMPANY, TODAY ANNOUNCED THAT IT IS SCHEDULED TO PARTICIPATE IN A FIRESIDE CHAT AT THE UPCOMING JEFFERIES LONDON HEALTHCARE CONFERENCE ON NOVEMBER 17, 2025 AT 4:30 PM (GMT) AND WILL PARTICIPATE IN ONE-ON-ONE MEETINGS ON NOVEMBER 17-18, 2025 IN LONDON, UK.

BIOMEA FUSION TO PARTICIPATE AT JEFFERIES LONDON HEALTHCARE CONFERENCE

SAN CARLOS, CALIF., NOV. 05, 2025 (GLOBE NEWSWIRE) -- BIOMEA FUSION, INC. (BIOMEA, BIOMEA FUSION OR THE COMPANY) (NASDAQ: BMEA), A CLINICAL-STAGE DIABETES AND OBESITY MEDICINES COMPANY, TODAY ANNOUNCED THE PRESENTATION OF TWO LATE BREAKING POSTERS AT OBESITYWEEK 2025 IN ATLANTA, GEORGIA.

BIOMEA FUSION SHOWCASES PRECLINICAL ADVANCES FOR BMF-650 AND ICOVAMENIB WITH LOW DOSE SEMAGLUTIDE AT OBESITYWEEK 2025

ADVANCES DIABETES AND OBESITY PROGRAMS WITH ICOVAMENIB DEMONSTRATING DURABLE 52-WEEK PHASE II DATA AND WITH BMF-650, BIOMEA'S NEXT-GENERATION, ORAL SMALL MOLECULE GLUCAGON-LIKE PEPTIDE-1 (GLP-1) RECEPTOR AGONIST (RA), DOSING ITS FIRST PATIENT IN A PHASE I CLINICAL TRIAL PRESENTED PRECLINICAL ACTIVITY OF ICOVAMENIB IN COMBINATION WITH SEMAGLUTIDE IN TYPE 2 DIABETES (T2D) ANIMAL MODEL AT EASD ANNUAL MEETING, DEMONSTRATING ENHANCED GLYCEMIC CONTROL AND BODY WEIGHT REDUCTION WITH PRESERVATION OF LEAN MASS RAISED APPROXIMATELY $68 MILLION IN GROSS PROCEEDS THROUGH TWO PUBLIC OFFERINGS, EXTENDING PROJECTED CASH RUNWAY INTO THE FIRST QUARTER OF 2027 SAN CARLOS, CALIF., NOV. 04, 2025 (GLOBE NEWSWIRE) -- BIOMEA FUSION, INC. (BIOMEA OR BIOMEA FUSION OR THE COMPANY) (NASDAQ: BMEA), A CLINICAL-STAGE DIABETES AND OBESITY COMPANY, TODAY REPORTED ITS FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2025, AND PROVIDED A BUSINESS UPDATE.

BIOMEA FUSION REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS AND CORPORATE HIGHLIGHTS

SAN CARLOS, CALIF., OCT. 30, 2025 (GLOBE NEWSWIRE) -- BIOMEA FUSION, INC. (BIOMEA) (NASDAQ: BMEA), A CLINICAL-STAGE DIABETES AND OBESITY MEDICINES COMPANY, TODAY ANNOUNCED THAT IT WILL PRESENT POSTER PRESENTATIONS AT OBESITYWEEK 2025, TAKING PLACE NOVEMBER 4-7, 2025 IN ATLANTA, GEORGIA.

BIOMEA FUSION TO PRESENT POSTER PRESENTATIONS AT OBESITYWEEK2025

SAN CARLOS, CALIF., OCT. 27, 2025 (GLOBE NEWSWIRE) -- BIOMEA FUSION, INC. (BIOMEA, BIOMEA FUSION OR THE COMPANY) (NASDAQ: BMEA), A CLINICAL-STAGE DIABETES AND OBESITY MEDICINES COMPANY, TODAY ANNOUNCED THAT THE FIRST PATIENT HAS BEEN DOSED IN A PHASE I CLINICAL TRIAL OF BMF-650, THE COMPANY'S INVESTIGATIONAL, NEXT-GENERATION ORAL SMALL MOLECULE GLUCAGON-LIKE PEPTIDE-1 (GLP-1) RECEPTOR AGONIST (RA).

Biomea Fusion, Inc.

BMEA

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Biomea Fusion, Inc.

BMEA.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

BMEA